ARBUTUS BIOPHARMA CORP (ABUS) — insider trading
Health Care · NASDAQ
ARBUTUS BIOPHARMA CORP (ABUS) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-06-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Beardsley Robert A | Director | Grant / award / vesting (derivative) | 78,800 | $0.00 | $0 | Form 4 |
| 2026-06-08 | Sawhney Roger | Director | Grant / award / vesting (derivative) | 78,800 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Androski Lindsay | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 71,700 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Androski Lindsay | Director, Officer (President and CEO) | Grant / award / vesting | 28,000 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 188,400 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting | 73,500 | $0.00 | $0 | Form 4 |
| 2025-08-04 | Sawhney Roger | Director | Grant / award / vesting (derivative) | 157,600 | $0.00 | $0 | Form 4 |
| 2025-03-31 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 750,000 | $0.00 | $0 | Form 4/A |
| 2025-03-31 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 750,000 | $0.00 | $0 | Form 4 |
| 2025-03-18 | Androski Lindsay | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 310,422 | $0.00 | $0 | Form 4 |
| 2025-03-18 | Beardsley Robert A | Director | Grant / award / vesting (derivative) | 157,600 | $0.00 | $0 | Form 4 |
| 2025-03-18 | Hasija Anuj | Director | Grant / award / vesting (derivative) | 157,600 | $0.00 | $0 | Form 4 |
Ask the chat about ABUS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARBUTUS BIOPHARMA CORP (ABUS).
Last updated 2026-06-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.